Deutsche Bank analysts provided their views on AmerisourceBergen Corporation (NYSE:ABC) following their Investor Meeting with the company’s CEO and CFO, where the key takeaways were the company’s comfort with its recently issued fiscal 2023 guidance and the resilience of its core franchises.

The company called out the strength of the core drug wholesaling business and its ability to weather recent issues like the transition from a spread business to a fee-for-service business on the brand side and generic deflation on the high-volume part of the business, as the company now targets customer level profitability both on the buy side and sell side, as opposed to product level margins.

Looking forward, the company is positioning itself to be the first company drug manufacturers call to partner with from Phase III to post-approval, especially as cell and gene therapies continue to come to market and grow in importance as part of the product mix in the US and Europe.